Literature DB >> 19360379

Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress.

Subramanyam N Murthy1, Sergiy Sukhanov, Jennifer McGee, Joel A Greco, Surabhi Chandra, Patrice Delafontaine, Philip J Kadowitz, Dennis B McNamara, Vivian A Fonseca.   

Abstract

Diabetes and impaired glucose tolerance are associated with increased cardiovascular disease morbidity and mortality particularly after vascular injury. Since insulin is frequently used in such patients, the effect of glulisine (short acting) and glargine (long acting) were tested in Zucker fatty rat carotid artery subjected to balloon catheter injury. Insulin-resistant Zucker fatty rats were sc injected 0.45 mg/kg/d of glargine (once) or glulisine (twice) for 1 week before, and 3 weeks after balloon injury. Fasting and postprandial glucose was measured twice weekly. Injured and uninjured carotid arteries, liver, and aorta were harvested after 3 weeks of injury. Carotid sections were H&amp;E stained for measuring intima/media ratio or immunostained for nitrotyrosine. Serum and aortic protein were analyzed for IGF-1 and 8-isoprostane, respectively. Carotid intima/media ratio was significantly reduced in the glargine group [0.9 +/- 0.1-control; 0.6 +/- 0.1-glulisine; 0.4 +/- 0.1-glargine, P < 0.05]. Serum IGF-1 levels were higher in both insulins, but significant only in glargine group [567 +/- 121 (ng/ml)-control; 1059 +/- 150 (ng/ml)-glargine; P < 0.05]. The aortic 8-isoprostane levels decreased significantly in the glargine group [(921 vs. 2566 pg/mg protein; P < 0.05]. Compared to control nitrotyrosine staining intensity was significantly lower in both groups of insulin-treated rats; the lowest level was in the glargine group. Insulin glargine attenuates carotid intimal hyperplasia in nondiabetic Zucker fatty rat independent of glucose levels and support a valuable function for insulin in vascular disease that merits additional investigations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360379      PMCID: PMC3221412          DOI: 10.1007/s11010-009-0094-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  54 in total

Review 1.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Authors:  S M Grundy; I J Benjamin; G L Burke; A Chait; R H Eckel; B V Howard; W Mitch; S C Smith; J R Sowers
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

Review 2.  Beneficial effects of insulin on endothelial function, inflammation, and atherogenesis and their implications.

Authors:  Louis Kuritzky; Scott E Nelson
Journal:  J Fam Pract       Date:  2005-06       Impact factor: 0.493

3.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 4.  Cardiological aspects of growth hormone and insulin-like growth factor-I.

Authors:  G Lombardi; A Colao; A Cuocolo; S Longobardi; C Di Somma; F Orio; B Merola; E Nicolai; M Salvatore
Journal:  J Pediatr Endocrinol Metab       Date:  1997 Nov-Dec       Impact factor: 1.634

5.  Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

Authors:  D R Clemmons; A C Moses; A Sommer; W Jacobson; A D Rogol; M R Sleevi; G Allan
Journal:  Growth Horm IGF Res       Date:  2005-08       Impact factor: 2.372

6.  Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.

Authors: 
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

Review 7.  Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.

Authors:  Ali A Jawa; Vivian A Fonseca
Journal:  Cardiol Clin       Date:  2005-05       Impact factor: 2.213

8.  Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity.

Authors:  M Federici; O Porzio; D Lauro; P Borboni; B Giovannone; L Zucaro; M L Hribal; G Sesti
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

9.  IGF-I increases forearm blood flow without increasing forearm glucose uptake.

Authors:  M Pendergrass; E Fazioni; D Collins; R A DeFronzo
Journal:  Am J Physiol       Date:  1998-08

10.  Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy.

Authors:  E Chantelau
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

View more
  2 in total

Review 1.  IGF-1, oxidative stress and atheroprotection.

Authors:  Yusuke Higashi; Sergiy Sukhanov; Asif Anwar; Shaw-Yung Shai; Patrice Delafontaine
Journal:  Trends Endocrinol Metab       Date:  2010-01-12       Impact factor: 12.015

2.  Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.

Authors:  Yanli Li; Jia Zheng; Yunfeng Shen; Wangen Li; Meimei Liu; Jun Wang; Surong Zhu; Meihua Wu
Journal:  Med Sci Monit       Date:  2018-05-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.